{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:59:32Z","timestamp":1791280772473,"version":"4.1.0"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TCRM"],"DOI":"10.2147\/tcrm.s71839","type":"journal-article","created":{"date-parts":[[2015,7,29]],"date-time":"2015-07-29T00:20:11Z","timestamp":1438129211000},"page":"1113","source":"Crossref","is-referenced-by-count":8,"title":["New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab"],"prefix":"10.2147","author":[{"given":"Arpita","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2015,7]]},"container-title":["Therapeutics and Clinical Risk Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=26168","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T22:45:15Z","timestamp":1477867515000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.dovepress.com\/new-developments-in-the-treatment-of-chronic-lymphocytic-leukemia-role-peer-reviewed-article-TCRM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/tcrm.s71839","relation":{},"ISSN":["1178-203X"],"issn-type":[{"value":"1178-203X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}